Boston Scientific said net sales for Q2 2025 were $5.061 billion, compared to $4.120 billion in the prior-year period, an increase of $941 million or 22.8%. The increase included operational net sales growth of 21.6% and the positive impact of 120 basis points from foreign currency fluctuations.

1. 01

   Boston Scientific said net sales for Q2 2025 were $5.061 billion, compared to $4.120 billion in the prior-year period, an increase of $941 million or 22.8%. The increase included operational net sales growth of 21.6% and the positive impact of 120 basis points from foreign currency fluctuations.

2. 02

   The company cited strong commercial execution across its businesses as the primary driver of the net sales increase, particularly in its Electrophysiology business unit, which was led by the rapid adoption of its Farapulse Pulsed Field Ablation System that launched in the U.S. in 2024.

3. 03

   Boston Scientific said reported net income attributable to Boston Scientific common stockholders for Q2 2025 was $797 million, or $0.53 per diluted share, and that excluding certain charges and credits totaling $330 million (after-tax), adjusted net income attributable to Boston Scientific common stockholders was $1.127 billion, or $0.75 per diluted share.

4. 04

   The company said Cardiology net sales for Q2 2025 were $2.647 billion, representing 52% of consolidated net sales, and increased $600 million, or 29.3%, compared to the prior-year period. It also announced the discontinuation of worldwide sales of the ACURATE Neo2 and ACURATE Prime Aortic Valve Systems in the same quarter.

Key figures

Quarter ended June 30, 2025

Revenue

$5.1B

Operating income

$819M

Net income

$795M

EPS

$0.53

Gross profit

$3.4B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.